TD
Todd C Davis (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). Across 1 priced purchase filing, the average 21-session return was -5.4% from execution and -2.9% from disclosure (delay-adjusted; derived). The largest single filing was $986K of PTHS (35,445 sh × $27.80, as filed), executed Jun 11. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-5.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-2.9%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$986K
shares × price, as filed
Last traded
Jun 11
Filed Jun 15
Median ADV $104.4M across their filed names
Open performance→Volume by month
Buys $2.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
LGNDRecent filings
PTHSPURCHASE
Pelthos Therapeutics Inc.
View filing →
$986K35,445 sh × $27.80
Exec Jun 11
Filed Jun 15 · 5:25 PM ET LGNDPURCHASE Ligand Pharmaceuticals Incorporated View filing → $1.0M
9,510 sh across 3 lots
Exec May 9 2025
Filed May 13 2025 · 5:30 PM ET